Bristol Myers to Buy RayzeBio for $4.1 Billion

Bristol Myers Squibb said Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second large deal struck by the drugmaker in less than a week.

Read Full Article (External Site)